Department of Dermatology, Tufts Medical Center, 800 Washington Street #114, Boston, MA 02111, USA.
BMC Med. 2013 Apr 4;11:96. doi: 10.1186/1741-7015-11-96.
Advancements in phosphodiesterase (PDE)-targeted therapies have shown promise in recent years for treating patients with a variety of autoimmune diseases. This review summarizes the development of PDE4 inhibitors and the associated literature with a focus on treatments for autoimmune diseases. After the initial investigations of the prototypic PDE inhibitor, rolipram, more selective inhibitors targeting the PDE4 isozyme have been developed. With phase II and phase III clinical trials currently underway to evaluate the safety and efficacy of the latest generation of PDE4 inhibitors, namely apremilast, a new class of treatments may be around the corner for patients suffering from chronic, autoimmune diseases.
近年来，磷酸二酯酶（PDE）靶向治疗的进展为治疗各种自身免疫性疾病的患者带来了希望。本综述总结了 PDE4 抑制剂的发展及其相关文献，重点关注自身免疫性疾病的治疗。在最初对原型 PDE 抑制剂罗利普兰进行研究后，针对 PDE4 同工酶的更具选择性的抑制剂已被开发出来。目前正在进行 II 期和 III 期临床试验，以评估最新一代 PDE4 抑制剂阿普司特的安全性和有效性，对于患有慢性自身免疫性疾病的患者来说，一类新的治疗方法可能即将问世。
